Arzerra 1000mg Solution for Infusion
Marketer
Glaxo SmithKline Pharmaceuticals Ltd
Salt Composition
Ofatumumab (20mg/ml)
Overview Arzerra 1000mg Solution for Infusion
Ofatumumab 1000mg intravenous infusion treats chronic lymphocytic leukemia (CLL), a type of blood cancer. It targets receptors on leukemia cells, marking them for elimination by the body's natural defenses. Administered intravenously under medical supervision, the dosage and frequency are determined by your physician based on your condition and may vary. Strict adherence to your doctor's instructions is crucial; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinue use only as directed by your doctor. Common side effects include nausea, diarrhea, shortness of breath, and cough. Report any concerning or persistent side effects to your physician promptly. Regular blood tests monitor blood cell counts and assess heart, liver, and kidney function. Prior to treatment, disclose any pre-existing heart, liver, or kidney conditions, and all medications, including those for infections, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception for both partners is essential throughout the treatment period.
Uses of Arzerra 1000mg Solution for Infusion
Chronic lymphocytic leukemia, a type of blood malignancy
Major Benefits of Arzerra 1000mg Solution for Infusion:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Arzerra 1000mg Solution for Infusion:
- Nausea
- Diarrhea
- Breathlessness
- Cough
- Flushing of skin
- Low energy
- Skin rash
How to use Arzerra 1000mg Solution for Infusion:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Arzerra 1000mg Solution for Infusion works:
Ofatumumab 1000mg, a monoclonal antibody solution for intravenous infusion, targets specific receptors on malignant cells, marking them for elimination by the patient's own immune response.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Arzerra 1000mg Infusion Solution has unknown safety implications. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Arzerra 1000mg Infusion Solution during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Patient consultation with their doctor is recommended.
Breast feedingSAFE IF PRESCRIBED
The infusion solution, Arzerra 1000mg, is likely safe for use while breastfeeding. Available human data indicates minimal infant risk associated with the medication.
DrivingCONSULT YOUR DOCTOR
The effect of Arzerra 1000mg Infusion Solution on driving ability is unknown. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Ofatumumab 1000mg infusion is suitable for use in individuals with renal impairment. No alteration of the Ofatumumab 1000mg infusion dosage is advised.
LiverUNSAFE
Patients with liver impairment should likely not receive Arzerra 1000mg Infusion Solution; its use is discouraged. Medical advice is recommended.
What if you forget to take Arzerra 1000mg Solution for Infusion :
NA
Facts to Know About Arzerra 1000mg Solution for Infusion
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Action Class | Anti-CD20 Antibody |
3,018 People bought this recently